WMSA
IOVA icon

Weiss Multi-Strategy Advisers’s Iovance Biotherapeutics IOVA Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-29,996
Closed -$331K – 699
2022
Q2 		$331K Sell
29,996
-25,004
-45% -$328K 0.01% 578
2022
Q1 		$916K Sell
55,000
-14,861
-21% -$230K 0.02% 513
2021
Q4 		$1.33M Sell
69,861
-5,139
-7% -$113K 0.03% 443
2021
Q3 		$1.85M Buy
75,000
+9,065
+14% +$214K 0.04% 425
2021
Q2 		$1.72M Buy
65,935
+34,874
+112% +$906K 0.04% 426
2021
Q1 		$983K Buy
31,061
+11,936
+62% +$495K 0.02% 485
2020
Q4 		$887K Sell
19,125
-21,426
-53% -$851K 0.02% 502
2020
Q3 		$1.33M Buy
40,551
+1,465
+4% +$44.9K 0.04% 397
2020
Q2 		$1.07M Buy
39,086
+10,086
+35% +$332K 0.03% 399
2020
Q1 		$868K Sell
29,000
-2,000
-6% -$53K 0.03% 313
2019
Q4 		$858K Buy
31,000
+11,500
+59% +$262K 0.01% 502
2019
Q3 		$355K Buy
+19,500
New +$431K 0.01% 513

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Weiss Multi-Strategy Advisers's IOVA Position: Q3 2022 in Review

Weiss Multi-Strategy Advisers sold out of Iovance Biotherapeutics (IOVA) in Q3 2022, closing a stake of 29,996 shares — an estimated $331K sold.

Weiss Multi-Strategy Advisers first reported a position in IOVA in Q3 2019 and held it in 12 quarters. The position peaked at $1.85M in Q3 2021. 242 funds tracked by Wall St. Rank hold IOVA as of Q3 2022.

  • Weiss Multi-Strategy Advisers reported no remaining Iovance Biotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 29,996 Iovance Biotherapeutics shares in Q3 2022, an estimated $331K.
  • Weiss Multi-Strategy Advisers first reported a position in Iovance Biotherapeutics in Q3 2019 and held it in 12 quarters.
  • Weiss Multi-Strategy Advisers's Iovance Biotherapeutics position peaked at $1.85M in Q3 2021.
  • 242 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q3 2022.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2022, filed 14 Nov 2022.